# OnCo record zelgen (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/zelgen/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "zelgen" ;
  schema:name "Suzhou Zelgen Biopharmaceuticals"@en ;
  schema:alternateName "Zelgen"@en, "泽璟制药"@en ;
  schema:description "Zelgen developed donafenib, the deuterated sorafenib that beat the original in first-line liver cancer and was approved in China in 2021."@en ;
  schema:url <https://onco.cc/companies/zelgen/>, <https://www.zelgen.com/en/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.zelgen.com/en/> ;
  onco:tag "china" ;
  schema:addressCountry "CN" ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/donafenib/>, <https://onco.cc/drugs/zg006/> ;
  onco:trials <https://onco.cc/trials/zgdh3/>, <https://onco.cc/trials/nct05978284/>, <https://onco.cc/trials/nct06283719/>, <https://onco.cc/trials/nct07038096/>, <https://onco.cc/trials/nct06558227/>, <https://onco.cc/trials/nct06903377/>, <https://onco.cc/trials/nct07258121/>, <https://onco.cc/trials/nct06440057/>, <https://onco.cc/trials/nct05584800/>, <https://onco.cc/trials/nct06938880/>, <https://onco.cc/trials/nct06883526/>, <https://onco.cc/trials/nct06927687/> .